Sonoma Pharmaceuticals, Inc. SNOA
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
2/9
Piotroski F — financial health
-44.4
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2026 | $19.5M | -$3.2M | $7.4M | -$4.1M | $3.1M |
| 2025 | $14.3M | -$3.5M | $5.5M | -$168,000 | $4.4M |
| 2024 | $12.7M | -$4.8M | $4.7M | -$2.4M | $6.1M |
| 2023 | $13.3M | -$5.2M | $4.5M | -$6.4M | $8.0M |
| 2022 | $12.6M | -$5.1M | $4.0M | -$4.4M | $8.7M |
| 2021 | $18.6M | -$4.0M | $6.6M | -$3.6M | $5.4M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -44.4 (distress)
- Working capital / assets 0.521
- Retained earnings / assets -14.397
- EBIT / assets -0.176
- Equity / liabilities 0.285
Source: SEC EDGAR filings · CIK 0001367083 · as of 2026-03-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.